Milestone! World's First Ovarian Dual Activation Technology Assists Patients in Conception
Release time:
2025-01-15
Recently, a major breakthrough in the field of reproductive health has garnered wide attention. The "ovarian dual activation" technology, collaboratively developed by the Yinfeng Life Sciences Research Institute (referred to as "Yinfeng Life Sciences") and the team of Professor Wang Huiying and Dr. Jin Bo from the Shenzhen Hospital of Beijing University of Chinese Medicine (referred to as "the hospital"), has achieved another milestone in cryobiomedical technology. Using methods of "cryopreservation + PFC", this technology has helped two patients achieve natural conception, providing new hope for women of childbearing age who are cancer patients, infertile, or of advanced maternal age.
This is reportedly the first global instance of using this method for ovarian activation and achieving successful natural conception. The application of this technology not only brings blessings to patients with premature ovarian insufficiency and infertility but also offers a novel solution for preserving the fertility of female cancer patients of childbearing age. In China, at least one million children and women of childbearing age face the risk of iatrogenic premature ovarian insufficiency annually. Currently, ovarian tissue cryopreservation and transplantation are regarded as one of the most promising fertility preservation methods internationally.
World's First Ovarian Dual Activation Technology Assists Two Patients in Natural Conception
The team innovatively combined the in vitro cryo-activation technology (IVA) of primordial follicles with the platelet-free plasma (PFC) technology extracted from autologous veins, providing a safer, more effective, and personalized treatment solution for patients with premature ovarian insufficiency (POI) and poor ovarian response (POR).
Traditional IVA technology processes ovarian tissues externally using drug or non-drug methods; however, it presents issues like damaging primordial follicle DNA, low safety, and activation efficiency. The Yinfeng Life Sciences along with the team led by Wang Huiying and Jin Bo from the hospital applied several innovative technologies, adopting in vitro vitrification cryo-activation of ovarian tissues combined with the dual activation of PFC, establishing a new, safe, and effective technology for activating primordial follicles.
PFC technology employs special methods to concentrate, activate, and separate various growth factors, cytokines, and related proteins from autologous venous blood, followed by freeze-drying and other standardized preparation processes. Clinical studies have proven these endogenous growth factors and cytokines can aid tissue regeneration, including activating dormant primordial follicles, promoting angiogenesis, and increasing ovarian volume.
For POI/POR patients, follicles in the ovaries are difficult to activate and grow using traditional methods. The team's innovative IVA technology involves taking a small piece of ovarian cortical tissue via laparoscopic surgery, employing low-temperature cryo-revival technology for low-temperature activation processing in the laboratory. About an hour later, the tissue is transplanted in situ, making the previously atrophied ovarian tissue soft and supple again. Postoperative assessments showed improvements in ovarian volume, follicle count, and ovarian arterial blood flow, with hormone levels returning to normal.
Currently, the team has performed PFC ovarian activation on over 300 POI/POR patients and conducted data analyses on 11 cases of ovarian tissue cryo-activation technology. Results indicated the technology significantly improved ovarian function in patients, activated dormant follicles, and partially restored fertility. Among the 11 cases of ovarian tissue cryo-activation transplantation, two patients successfully achieved natural conception after three months of treatment.
Ovarian Cryo-Activation: Cryogenic Technology Safeguards Female Fertility
Experts note that the ovarian dual activation technology not only provides a safe and reliable new technology for POI/POR patients but also offers options for fertility preservation in cancer patients.
Fertility preservation, in essence, is a comprehensive solution integrating surgery, drugs, and laboratory technologies, aiming to protect human reproductive capabilities and ensure the continuous inheritance of genetic information. For women, fertility preservation mainly covers oocyte freezing, embryo freezing, and ovarian tissue freezing techniques. For men, sperm freezing is the main method to preserve fertility. Ovarian tissue cryopreservation and transplantation are currently seen as the most promising fertility preservation methods internationally, serving as the sole fertility preservation method for prepubescent girls and women of childbearing age who cannot delay cancer treatment.
The technology also shows potential for application in menopause management. By preserving part of the ovarian tissue at a young age through deep cryogenic preservation and transplanting it at an older age, menopause can be delayed, substituting hormone treatments and helping to slow down aging.
In the future, Yinfeng Life Sciences will collaborate with the Shenzhen Hospital of Beijing University of Chinese Medicine (Longgang) to continue original technological research in "fertility preservation technology," aiming to establish a complete and comprehensive fertility preservation system, extensively and effectively applying cryopreservation technology in clinical fertility preservation, contributing to building a fertility-friendly society.
We have reason to believe that cryobiomedical technology will become increasingly mature in larger scales, involving more complex organs and complete life forms. Whether in terms of "walking upright" in time or future Mars colonization, the development prospects of cryobiomedical technology deserve our shared anticipation.
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
